Northwire Canada EditionMonday, July 13, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory

Verano Founder and Chief Executive Officer George Archos Shares Celebratory Comments on Cannabis Rescheduling Announcement

VRNO · Price

Executive Summary

  • President Donald Trump issued an Executive Order rescheduling cannabis from Schedule I to Schedule III, a historic policy shift that could unlock banking, tax, and research opportunities for Verano.
  • The company highlighted the potential to list its shares on a U.S.–based exchange and expand federal reform benefits across the industry.
  • Management expressed optimism that the change will drive economic growth, job creation, and increased tax revenues nationwide.

Key Details

  • Executive Order directs the Department of Justice to reclassify cannabis under the Controlled Substances Act from Schedule I to Schedule III.
  • Verano anticipates “critical banking and regulatory reforms” as a direct result of the rescheduling.
  • The company foresees new opportunities for listing on a U.S. stock exchange, expanding capital‑raising options.
  • CEO George Archos quoted: “Today’s historic cannabis rescheduling announcement marks a significant milestone… unlocking economic growth and reversing decades of harmful prohibitionist policies.”
  • No immediate financial figures disclosed; the release focuses on strategic implications and future outlook.

Notable Quotes

“We’re grateful to President Trump for recognizing the overwhelming majority of Americans who support cannabis rescheduling, opening the door to federal reform, medical research, and normalization for an industry that employs hundreds of thousands of professionals and contributes billions of dollars in taxes and economic activity every year.” – George Archos, Founder & CEO


Read the original news release →

More from VERANO HOLDINGS CORP.